Ethiopia is taking steps to begin producing cancer treatment drugs locally, as part of broader efforts to reduce reliance on imports and strengthen the country’s healthcare system.
Currently, Ethiopia imports all medications used in cancer treatment.
However, a feasibility study is underway to assess the viability of domestic production.
Investors have already entered the Kilinto Pharmaceutical Special Economic Zone to initiate projects aimed at manufacturing cancer drugs locally.
The Armauer Hansen Research Institute is expected to play a key role in supporting these initiatives. Assistant Professor Mesay W/Mariam, Deputy Director of the Pharmaceutical Industry Development Sector at the institute, said the research will help determine whether local production is more viable than continued reliance on imports.
He noted that domestic manufacturing could significantly reduce the country’s dependence on imported medicines and improve access to essential treatments.
The government is also giving increased attention to the pharmaceutical sector, with efforts focused on ensuring sustainable production and strengthening national drug security.
However, challenges remain. Ongoing fuel shortages and transportation disruptions linked to tensions in the Middle East could pose risks to the supply chain and production process.
According to the Ministry of Health, Ethiopia currently meets about 42 percent of its pharmaceutical demand through local production.
Expanding domestic capacity is seen as critical to closing this gap.
Health experts also warn that delays in diagnosis and treatment are contributing to rising cancer-related deaths.
Breast cancer is the leading cause of cancer mortality among women in Ethiopia, while cervical cancer remains another major threat.
Among children, leukemia is one of the most commonly diagnosed cancers, according to a study conducted in Addis Ababa and published by the National Institutes of Health (NIH).
Lelisa Amanuel, Senior Advisor to the Ministry of Health, said late diagnosis continues to be a major barrier to effective treatment, significantly reducing patients’ chances of survival.
He added that cancer cases in Ethiopia are steadily increasing, with more than 83,000 new cases reported each year placing growing pressure on the healthcare system.
Globally, cancer remains one of the leading causes of death, with approximately 19 million new cases and 10 million deaths annually.
About 75 percent of these deaths occur in low- and middle-income countries, where access to early diagnosis and advanced treatment is limited.
Children are also heavily affected. According to health officials, around 400,000 children are diagnosed with cancer worldwide each year, with the vast majority of cases occurring in low-income settings.
The planned local production of cancer drugs is expected to improve access to treatment and reduce costs, offering new hope for patients across Ethiopia.